JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 1991; 18:1610-1616
© 1991 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Voth, E
Right arrow Articles by Schroder, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Voth, E
Right arrow Articles by Schroder, R

Intravenous streptokinase in acute myocardial infarction (I.S.A.M.) trial: serial evaluation of left ventricular function up to 3 years after infarction estimated by radionuclide ventriculography. I.S.A.M. Study Group

E Voth, U Tebbe, H Schicha, KL Neuhaus, and R Schroder

Department of Nuclear Medicine, University of Gottingen, Germany.

The Intravenous Streptokinase in Acute Myocardial Infarction (I.S.A.M.) trial was a prospective, placebo-controlled, double-blind multicenter trial of high-dose short-term intravenous streptokinase in acute myocardial infarction administered within 6 h after the onset of symptoms. Global and regional left ventricular ejection fractions were determined by radionuclide ventriculography in a subset of 120 patients 3 days, 4 weeks, 7 months, 18 months and 3 years after acute myocardial infarction. In patients with anterior myocardial infarction, left ventricular ejection fraction was higher in the streptokinase than in the placebo group 3 days after acute infarction (49 +/- 14% vs. 40 +/- 11%, p = 0.02). This difference of about 10% units in ejection fraction persisted during the 3 year follow-up period. Among streptokinase-treated patients, regional left ventricular ejection fraction was higher within the infarct zone as well as in remote myocardium throughout the follow-up period. Among patients with inferior infarction, no significant differences between the treatment and control groups were demonstrable with respect to global and regional left ventricular ejection fraction. Thus, intravenous administration of streptokinase within 6 h after the onset of symptoms of acute myocardial infarction preserves left ventricular function over a period of greater than or equal to 3 years in patients with acute anterior myocardial infarction. It improves regional myocardial function within the infarct zone as well as in remote areas. In patients with acute inferior myocardial infarction, benefit from intravenous streptokinase is of only minor degree.


This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
D. J. Engelen, A. P. Gorgels, E. C. Cheriex, E. D. De Muinck, A. J. Oude Ophuis, W. R. Dassen, J. Vainer, V. G. van Ommen, and H. J. Wellens
Value of the electrocardiogram in localizing the occlusion site in the left anterior descending coronary artery in acute anterior myocardial infarction
J. Am. Coll. Cardiol., August 1, 1999; 34(2): 389 - 395.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Goto, H. Sakai, M. Goto, M. Ono, Y. Ikeda, S. Handa, and Z. M. Ruggeri
Enhanced Shear-Induced Platelet Aggregation in Acute Myocardial Infarction
Circulation, February 9, 1999; 99(5): 608 - 613.
[Abstract] [Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1991 by the American College of Cardiology Foundation.